Compare · BDX vs STIM
BDX vs STIM
Side-by-side comparison of Becton Dickinson and Company (BDX) and Neuronetics Inc. (STIM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and STIM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.58B, about 386.6x STIM ($112.7M).
- Over the past year, BDX is down 9.8% and STIM is down 58.2% - BDX leads by 48.4 points.
- BDX has been more active in the news (4 items in the past 4 weeks vs 3 for STIM).
- BDX has more recent analyst coverage (25 ratings vs 4 for STIM).
- Company
- Becton Dickinson and Company
- Neuronetics Inc.
- Price
- $158.16-1.07%
- $1.62-9.24%
- Market cap
- $43.58B
- $112.7M
- 1M return
- +8.93%
- +33.33%
- 1Y return
- -9.82%
- -58.25%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 4
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Neuronetics Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest STIM
- Large owner Chernett Jorey bought $62,300 worth of shares (35,000 units at $1.78), increasing direct ownership by 0.33% to 10,588,988 units (SEC Form 4)
- New insider Anderson Cory claimed ownership of 416,812 shares (SEC Form 3)
- Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
- SEC Form 8-K filed by Neuronetics Inc.
- Director Amin Avinash disposed of 42,500 shares, decreasing direct ownership by 59% to 30,000 units (SEC Form 4)
- Large owner Madryn Asset Management, Lp acquired 72,500 shares (SEC Form 4)
- Neuronetics Appoints Robert Greene as Senior Vice President Sales
- SEC Form SD filed by Neuronetics Inc.
- Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)
- Director Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)